BRPI0909630B8 - composição em suspensão aquosa particularmente adequada para injeção dentro do olho - Google Patents

composição em suspensão aquosa particularmente adequada para injeção dentro do olho

Info

Publication number
BRPI0909630B8
BRPI0909630B8 BRPI0909630A BRPI0909630A BRPI0909630B8 BR PI0909630 B8 BRPI0909630 B8 BR PI0909630B8 BR PI0909630 A BRPI0909630 A BR PI0909630A BR PI0909630 A BRPI0909630 A BR PI0909630A BR PI0909630 B8 BRPI0909630 B8 BR PI0909630B8
Authority
BR
Brazil
Prior art keywords
particularly suitable
injection
eye
aqueous suspension
suspension composition
Prior art date
Application number
BRPI0909630A
Other languages
English (en)
Inventor
P Kabra Bhagwati
Sarkar Ruma
Original Assignee
Alcon Inc
Alcon Res Llc
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc, Alcon Res Llc, Alcon Res Ltd filed Critical Alcon Inc
Publication of BRPI0909630A2 publication Critical patent/BRPI0909630A2/pt
Publication of BRPI0909630B1 publication Critical patent/BRPI0909630B1/pt
Publication of BRPI0909630B8 publication Critical patent/BRPI0909630B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição em suspensão aquosa particularmente adequada para injeção dentro do olho e usos da referida composição. a presente invenção refere-se a composição em suspensão de triancinolona acetonidas. as composições em suspensão possuem uma viscosidade relativamente baixa e são fáceis de extrusar através de uma agulha de calibre 27 ou 30, mas são altamente floculadas e facilmente dispersas novamente. as composições são particularmente adequadas para injeção intravitreal.
BRPI0909630A 2008-03-11 2009-03-10 composição em suspensão aquosa particularmente adequada para injeção dentro do olho BRPI0909630B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
US61/035,459 2008-03-11
PCT/US2009/036652 WO2009114521A1 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Publications (3)

Publication Number Publication Date
BRPI0909630A2 BRPI0909630A2 (pt) 2015-09-22
BRPI0909630B1 BRPI0909630B1 (pt) 2019-03-26
BRPI0909630B8 true BRPI0909630B8 (pt) 2021-05-25

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909630A BRPI0909630B8 (pt) 2008-03-11 2009-03-10 composição em suspensão aquosa particularmente adequada para injeção dentro do olho

Country Status (21)

Country Link
US (3) US8128960B2 (pt)
EP (1) EP2262506B1 (pt)
JP (1) JP5581227B2 (pt)
KR (1) KR101555293B1 (pt)
CN (1) CN101959519B (pt)
AR (1) AR070824A1 (pt)
AU (1) AU2009223649B2 (pt)
BR (1) BRPI0909630B8 (pt)
CA (1) CA2717605C (pt)
CL (1) CL2009000573A1 (pt)
DK (1) DK2262506T3 (pt)
ES (1) ES2471122T3 (pt)
MX (1) MX2010009974A (pt)
PL (1) PL2262506T3 (pt)
PT (1) PT2262506E (pt)
RU (1) RU2481842C2 (pt)
SI (1) SI2262506T1 (pt)
TW (1) TWI468165B (pt)
UY (1) UY31699A1 (pt)
WO (1) WO2009114521A1 (pt)
ZA (1) ZA201005839B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
RU2481842C2 (ru) * 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
KR20110099044A (ko) * 2008-12-22 2011-09-05 알콘 리서치, 리미티드 후안부에 유효농도의 활성제를 전달하기 위한 국소 안용액 조성물
WO2012051575A2 (en) 2010-10-15 2012-04-19 Iscience Interventional Corporation Device for ocular access
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
WO2015196085A2 (en) 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019136512A1 (en) * 2018-01-10 2019-07-18 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
CA3136814A1 (en) * 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
AU4472396A (en) 1994-12-30 1996-07-24 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
CA2336703A1 (en) 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
JP5000835B2 (ja) * 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
DE60233414D1 (de) * 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
RU2005129276A (ru) * 2003-02-20 2006-01-27 Алькон, Инк. (Ch) Применение стероидов для лечения субъектов, страдающих заболеванием глаз
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
JP2007516297A (ja) * 2003-12-23 2007-06-21 アルザ・コーポレーシヨン 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070225727A1 (en) 2004-05-31 2007-09-27 Keiichi Matsuhisa Transparent Tissue-Visualizng Preparation
US20060089590A1 (en) 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
US20080008762A1 (en) 2004-11-17 2008-01-10 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Steroid Formulation And Methods Of Treatment Using Same
CN101119733A (zh) * 2005-02-18 2008-02-06 参天制药株式会社 减轻或避免甾族化合物副作用的方法
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
RU2481842C2 (ru) * 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций

Also Published As

Publication number Publication date
US8128960B2 (en) 2012-03-06
CN101959519B (zh) 2013-03-20
CN101959519A (zh) 2011-01-26
PT2262506E (pt) 2014-06-24
US20120115829A1 (en) 2012-05-10
KR20100127267A (ko) 2010-12-03
HK1146464A1 (en) 2011-06-10
EP2262506B1 (en) 2014-05-07
CL2009000573A1 (es) 2010-01-04
US20120116216A1 (en) 2012-05-10
TWI468165B (zh) 2015-01-11
KR101555293B1 (ko) 2015-10-06
US8211880B2 (en) 2012-07-03
BRPI0909630B1 (pt) 2019-03-26
JP5581227B2 (ja) 2014-08-27
US20090233890A1 (en) 2009-09-17
ZA201005839B (en) 2011-10-26
CA2717605C (en) 2012-05-15
JP2011513492A (ja) 2011-04-28
EP2262506A1 (en) 2010-12-22
CA2717605A1 (en) 2009-09-17
AU2009223649A1 (en) 2009-09-17
WO2009114521A1 (en) 2009-09-17
MX2010009974A (es) 2010-09-30
SI2262506T1 (sl) 2014-07-31
DK2262506T3 (da) 2014-06-10
TW200940071A (en) 2009-10-01
BRPI0909630A2 (pt) 2015-09-22
RU2010141542A (ru) 2012-04-20
PL2262506T3 (pl) 2014-09-30
UY31699A1 (es) 2009-05-29
RU2481842C2 (ru) 2013-05-20
ES2471122T3 (es) 2014-06-25
AU2009223649B2 (en) 2013-08-29
AR070824A1 (es) 2010-05-05

Similar Documents

Publication Publication Date Title
BR112014003903A2 (pt) composições dentais que compreendem agentes de adição fragmentação
MX2010009974A (es) Suspensiones de acetonida de triamcinolona de baja viscosidad, altamente floculadas para inyeccion intravitrea.
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
WO2015028969A3 (en) Transduction buffer
BRPI0923702B8 (pt) Composições inseticidas estáveis compreendendo spinosin e uma mistura esteroisomérica de sulfoxaflor, e seu método de produção
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BRPI1105992B8 (pt) Composição para limpeza da pele
NZ751877A (en) Pertuzumab variants and evaluation thereof
EA201001639A1 (ru) Композиции и способы их получения и применения
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
EP4414376A3 (en) Novel depsipeptide and uses thereof
EA201691019A1 (ru) Композиции гиалуроновой кислоты, включающие мепивакаин
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BRPI0911907B8 (pt) processo para produzir uma composição contendo triptofano e composição proteica contendo triptofano
BR112015012972A2 (pt) método para tratar uma formação subterrânea, composição para tratamento de uma formação subterrânea, e, método para preparo de uma composição aquosa para tratamento de uma formação subterrânea
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
EP2528578A4 (en) DENTAL COMPOSITION USING A CALCIUM SOURCE
BR112015001728B8 (pt) composições de condicionador
BR112017023720A2 (pt) formulações de inibidor de corrosão
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: ALCON INC. (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)